Skip to main content
. 2011 May;55(5):2460–2462. doi: 10.1128/AAC.01358-10

Table 1.

Descriptions of the 10 patients with proven or probable invasive aspergillosis showing the site involved, underlying condition, antifungal treatment received, and outcome

Yr Clinical form Underlying condition Diagnosis Antifungal treatment Outcome Patient with mutant isolatesb
2001 Pericarditis and adenopathies HIV Proven Amphotericin B Poor D
2001 Pulmonary Hematological cancer Probable Amphotericin B Poor E
2002 Postsurgical Surgery Probable Itraconazole Survival
2002 Pulmonary COPDa Probable Amphotericin B Poor
2003 Postsurgical Surgery Probable Itraconazole Survival
2003 Pulmonary COPD Probable Caspofungin Poor
2006 Postsurgical mediastinitis Surgery Proven Voriconazole + caspofungin Poor B
2006 Pulmonary COPD Probable Voriconazole Survival
2007 Pulmonary COPD Probable Voriconazole Survival
2007 Pulmonary COPD Probable Voriconazole Survival
a

COPD, chronic obstructive pulmonary disease.

b

Patients infected with isolates harboring mutations in the cyp51A gene are identified by an alphabetical code.